10.04.2024 – 15:35
Gedeon Richter Plc.
Budapest, Hungary (ots/PRNewswire)
Cariprazine, a drug originally developed by the Hungarian pharmaceutical company Gedeon Richter Plc. developed antipsychotic, is available in 64 countries and has become a multiple blockbuster in the United States with sales of almost $3 billion. It is a unique achievement that a Hungarian drug candidate – discovered and developed locally – has received FDA and EU approval, and the company already has several more molecules in its pipeline.
“Thousands of psychiatrists came to Budapest for the European Psychiatry Congress, and perhaps even they are not aware of the important role Hungarian researchers play in this field worldwide. We have almost 1,200 researchers, making us the largest innovation base in the entire region. The fact that cariprazine has been among the top 100 drugs in sales for several years is an outstanding achievement comparable to winning an Olympic medal,” said Gábor Orbán, CEO of Richter, at a press conference on the occasion of the European Psychiatry Congress in Budapest.
Dr. István Greiner, Director of Richter’s Research and Development Department, told the story of the development of cariprazine. “It wasn’t a one-time success; We have already brought nine original medicines to market since the Second World War. Starting in 1998, we began focusing on the dopamine-3 receptor in the brain, and the efforts eventually led to cariprazine. It was approved by the FDA in 2015 for schizophrenia – the first approval in the history of the Hungarian pharmaceutical industry -, later in the EU, and its indications were approved in the USA first for the depressive episodes of bipolar depression I and in 2019 for the adjunctive treatment of patients with severe depressive disorders expanded. In a joint project with AbbVie, we hope for the success of our molecule for the treatment of a psychiatric disorder, which is currently in Phase I studies alongside three other candidates from our portfolio.”
Dr. Kristóf Kóczián, head of Richter’s CNS business unit, spoke about the drug’s global positioning and availability. “A total of 1.3 million patients have been treated with cariprazine since its launch, and it was the 46th best-selling innovative drug in 2023, with sales of nearly $3 billion and a real chance of becoming the best-selling atypical antipsychotic in history,” added Kóczian added.
Further information: Judge Gedeon
View original content: https://www.prnewswire.com/news-releases/gedeon-richter-cariprazin-hat-eine-reelle-chance-das-meistverkaufte-atypische-antipsychotikum-zu-werden-302113203.html
Press contact:
Zsuzsa Beke,
Head of Public Relations and Public Affairs,
Gedeon Richter Plc.,
[email protected],
+36 1 431 4888
Original content by: Gedeon Richter Plc., transmitted by news aktuell